Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Gregory B Lesinski"'
Autor:
Mark Yarchoan, Skylar Woolman, Lauren Dennison, Gregory B. Lesinski, Kayla Cruz, James M. Leatherman, Nilofer S. Azad, Elizabeth M. Jaffee, Aditya Mohan, Amanda Ruggieri
Publikováno v:
Cancer Immunol Res
MEK inhibition (MEKi) is proposed to enhance antitumor immunity but has demonstrated mixed results as an immunomodulatory strategy in human clinical trials. MEKi exerts direct immunomodulatory effects on tumor cells and tumor-infiltrating lymphocytes
Autor:
Michael Ware, Christopher McQuinn, Mohommad Zaidi, Hannah Knochelmann, Brian Robinson, Cameron Herting, Thomas Mace, Zhengjia Chen, Chao Zhang, Matthew Farren, Amanda Ruggieri, Jacob Bowers, Reena Shakya, Alton Farris III, Greg Young, William Carson III, Bassel El-Rayes, Chrystal Paulos, Gregory B. Lesinski
Pancreatic ductal adenocarcinoma (PDAC) is exceptionally resistant to immune checkpoint inhibition (ICI). We previously reported that elevated systemic interleukin-6 (IL-6) and increased numbers of T cells positive for circulating cytotoxic T-lymphoc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::31d2e3ec24546872434c9300ce2d0736
https://doi.org/10.21203/rs.3.rs-599225/v1
https://doi.org/10.21203/rs.3.rs-599225/v1
Autor:
Peyton C Kuhlers, Roberto Hernandez-Alejandro, Ashley B. Morrison, Gregory B. Lesinski, Katherine M. Jackson, Brian A. Belt, Nathania M Figueroa Guilliani, Luis I. Ruffolo, Paul R. Burchard, Jessica M Keilson, Jen Jen Yeh, Rachel Jewell, David C. Linehan, Luis E. De Las Casas, Shuyang S. Qin, Aram F. Hezel, Mary A. Georger, Laura M. Calvi, Nicholas A. Ullman, Benjamin S. Dale, Michael R. O'Dell, Peter Juviler, Timothy M Nywening
Publikováno v:
Gut. 71(7)
ObjectiveIntrahepatic cholangiocarcinoma (iCCA) is rising in incidence, and at present, there are limited effective systemic therapies. iCCA tumours are infiltrated by stromal cells, with high prevalence of suppressive myeloid populations including t
Autor:
Cameron Herting, Gregory B. Lesinski
The activity of the immune system under homeostasis and disease states is governed by complex interactions of cells both through direct cell–cell contact and the secretion of soluble immunomodulatory factors. In cancer, the tumor microenvironment i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a60c302b918c7abe73f426ed574c1015
https://doi.org/10.1007/13905_2021_1
https://doi.org/10.1007/13905_2021_1
Autor:
Matthew R. Farren, Yan Tong, Safi Shahda, Cameron Herting, Tanios Bekaii-Saab, Gregory B. Lesinski, Bert H. O'Neil, Bassel F. El-Rayes, Ziyue Liu, Christina Wu, Walid L. Shaib, Thomas A. Mace, Christopher McQuinn, Anne M. Noonan
Publikováno v:
Cancer Immunol Immunother
Modified FOLFOX6 is an established therapy for patients with metastatic colorectal cancer (mCRC). We conducted a single-arm phase Ib study to address the hypothesis that addition of pembrolizumab to this regimen could safely and effectively improve p
Autor:
Shuhua Wang, Gregory B. Lesinski, Bassel F. El-Rayes, Rohan K. Dhamsania, Susan N. Thomas, Sanjay Chandrasekaran, Brandon Ware, Mohammad Y. Zaidi, Edmund K. Waller, Sruthi Ravindranathan, Passang Tenzin, Anish Majumdar, Jingru Zhu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Pancreatic ductal adenocarcinoma (PDAC), the fourth leading cause of cancer related death in the U.S, has a 5-year survival rate of only 10%.1 The paucity of T cells in the immune privileged tumor microenvironment (TME) is a major limitati
Autor:
Susan N. Thomas, Haydn T. Kissick, Brian S. Robinson, Mohammad Y. Zaidi, Rohan K. Dhamsania, Gregory B. Lesinski, Alan B. Frey, Shuhua Wang, Sanjeev Gumber, Michael B. Ware, Jingru Zhu, Yuan Liu, Maria Cardenas, Passang Tenzin, Gaurav N. Joshi, Anish Sen-Majumdar, Shanmuganathan Chandrakasan, Sruthi Ravindranathan, Bassel F. El-Rayes, Jian-Ming Li, Edmund K. Waller
Publikováno v:
Cancer Research. 81:PO-072
Pancreatic ductal adenocarcinoma (PDAC) is unresponsive to immune checkpoint therapy largely due to a paucity of T cells within the tumor microenvironment (TME) and abundant immunosuppressive signaling pathways. In this study we show that human PDAC
Autor:
Cameron Herting, Yuchen Zhang, Kavita M. Dhodapkar, Shishir K. Maithel, Mohammad Y. Zaidi, Christina Wu, Mehmet Akce, Amanda Ruggieri, Bassel F. El-Rayes, Madhav V. Dhodapkar, Gregory B. Lesinski, Olatunji B. Alese, Juan M. Sarmiento, Michael B. Ware, Deon B. Doxie, Rafi Ahmed
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundPancreatic ductal adenocarcinoma (PDAC) has yet to widely benefit from T cell-targeted immunotherapy and displays universally poor prognosis. Thus, enhancing the activity of immunotherapy is a high priority. Our laboratory recently reported
Autor:
Gregory B. Lesinski
Publikováno v:
Gut
OBJECTIVE: This study exploits the intersection between molecular-targeted therapies and immune-checkpoint inhibition to define new means to treat pancreatic cancer. DESIGN: Patient-derived cell lines and xenograft models were used to define the resp
Publikováno v:
Journal for Immunotherapy of Cancer
Pancreatic ductal adenocarcinoma (PDAC) is plagued by a dismal 5-year survival rate, early onset of metastasis and limited efficacy of systemic therapies. This scenario highlights the need to fervently pursue novel therapeutic strategies to treat thi